DBMR Logo
Request for TOC Request for Sample
BUY NOW

Global Oligonucleotide Synthesis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Healthcare | Upcoming Report | Apr 2024 | Global | 350 Pages | No of Tables: 220 | No of Figures: 60
Buy Now Nucleus

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Oligonucleotide Synthesis Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Global Oligonucleotide Synthesis Market size in 2024 - 8.60 and 2032 - 21.01, highlighting the projected market growth. USD 8.60 Billion USD 21.01 Billion 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size(Base Year)
USD 8.60 Billion
Diagram Market Size (Forecast Year)
USD 21.01 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Agilent Technologies
  • Atdbio
  • LGC Limited
  • BioSynthesis
  • Eurofins Genomics

Global Oligonucleotide Synthesis Market Segmentation, By Product (Oligonucleotide, Reagents, and Equipment), Type (Custom Oligos and Predesigned Oligos), Application (Therapeutic Applications, Diagnostics, Research, and Others), End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, and Others) - Industry Trends and Forecast to 2032

Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market Size

  • The global oligonucleotide synthesis market size was valued at USD 8.60 billion in 2024 and is expected to reach USD 21.01 billion by 2032, at a CAGR of 11.80% during the forecast period
  • The market growth is largely fueled by the growing use of synthesized oligonucleotides for therapeutic and diagnostic applications, ongoing advancements in technologies such as next-generation sequencing (NGS) and CRISPR, and increasing investments by governments and major players in life science research
  • Furthermore, the rising demand for personalized medicine, a strong clinical pipeline for oligonucleotide-based drugs, and increasing focus on developing targeted therapies for a wide range of diseases are establishing oligonucleotides as crucial tools in drug development and molecular biology

Oligonucleotide Synthesis Market Analysis

  • Oligonucleotides, short DNA or RNA sequences, are fundamental building blocks in life sciences, vital for applications across genomics research, diagnostics, and therapeutic development. Their increasing precision and versatility are positioning them as indispensable tools in modern biotechnology
  • The escalating demand for oligonucleotide synthesis is primarily fueled by the burgeoning field of personalized medicine, growing investments in life science R&D, and the widespread adoption of advanced technologies such as Next-Generation Sequencing (NGS) and CRISPR gene editing. The robust pipeline of oligonucleotide-based drugs also plays a significant role in market expansion
  • North America dominates the oligonucleotide synthesis market with the largest revenue share of 40.7% in 2024, characterized by its well-established biotechnology and pharmaceutical industries, substantial R&D spending, and early adoption of cutting-edge biotechnologies. The region benefits from a strong presence of key industry players and significant investments in genomics and precision medicine initiatives
  • Asia-Pacific is expected to be the fastest growing region in the oligonucleotide synthesis market during the forecast period due to increasing biotech investments, growing academic research, rising healthcare expenditure, and supportive government policies aimed at enhancing genomics and precision medicine
  • Therapeutic Applications segment dominates the oligonucleotide synthesis market with a market share of 42.7% in 2024, driven by the increasing number of regulatory approvals for oligonucleotide-based drugs for various neurological and rare diseases, along with a growing focus on personalized medicine and the potential of these drugs to treat previously untreatable conditions

Report Scope and Oligonucleotide Synthesis Market Segmentation  

Attributes

Oligonucleotide Synthesis Key Market Insights

Segments Covered

  • By Product: Oligonucleotide, Reagents, and Equipment
  • By Type: Custom Oligos and Predesigned Oligos
  • By Application: Therapeutic Applications, Diagnostics, Research, and Others
  • By End User: Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, and Others

Countries Covered

North America

  • U.S.
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • U.K.
  • Netherlands
  • Switzerland
  • Belgium
  • Russia
  • Italy
  • Spain
  • Turkey
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of Asia-Pacific

Middle East and Africa

  • Saudi Arabia
  • U.A.E.
  • South Africa
  • Egypt
  • Israel
  • Rest of Middle East and Africa

South America

  • Brazil
  • Argentina
  • Rest of South America

Key Market Players

  • Integrated DNA Technologies, Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Twist Bioscience (U.S.)
  • Merck KGaA (Germany)
  • Agilent Technologies, Inc. (U.S.)
  • Eurofins Scientific (Luxembourg)
  • LGC Limited (U.K.)
  • GenScript (U.S.)
  • Danaher Corporation (U.S.)
  • Sarepta Therapeutics, Inc. (U.S.)
  • Ionis Pharmaceuticals, Inc. (U.S.)
  • Alnylam Pharmaceuticals, Inc. (U.S.)
  • Nitto Avecia (U.S.)
  • TriLink BioTechnologies (U.S.)
  • Bio-Synthesis Inc. (U.S.)
  • Ajinomoto Bio-Pharma (Japan)
  • ATDBio Ltd (U.K.)
  • Microsynth AG (Switzerland)
  • Macrogen Inc. (South Korea)
  • Kaneka Eurogentec S.A. (Belgium)

Market Opportunities

  • Advancements in Genomics and Personalized Medicine
  • Regulatory Support and Approval of Oligonucleotide Therapeutics

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, pricing analysis, brand share analysis, consumer survey, demography analysis, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Oligonucleotide Synthesis Market Trends

“Advancements in Automation and High-Throughput Technologies”

  • A significant and accelerating trend in the global oligonucleotide synthesis market is the deepening integration of automation and high-throughput technologies. This advancement is fundamentally transforming the efficiency, scalability, and cost-effectiveness of oligonucleotide production, which is crucial for various applications, from basic research to drug development

    • For instance, automated synthesizers such as the MerMade series can produce hundreds of oligonucleotides simultaneously, dramatically increasing throughput. The integration of array-based synthesis and other advanced chemistries allows for the rapid and parallel synthesis of numerous sequences on a single platform, enhancing efficiency and reducing manual errors

  • Automation in oligonucleotide synthesis extends beyond just production. It encompasses streamlined workflows, from reagent dispensing to purification and quality control. This leads to higher reproducibility, reduced labor costs, and a faster turnaround time, which are critical in research and clinical settings. Furthermore, advancements in enzymatic synthesis methods are offering more environmentally friendly and scalable alternatives to traditional chemical synthesis
  • The seamless integration of high-throughput capabilities allows researchers and pharmaceutical companies to conduct large-scale screening and develop a wider range of oligonucleotide-based therapeutics and diagnostics more rapidly. This is particularly vital for precision medicine, where customized oligonucleotide sequences are needed for individual patient profiles
  • This trend towards more automated, precise, and efficient oligonucleotide synthesis systems is fundamentally reshaping the landscape of drug discovery and genomics research. Consequently, companies are continuously investing in R&D to develop more sophisticated and integrated platforms that can meet the growing demand for complex and high-quality oligonucleotides
  • The demand for oligonucleotide synthesis solutions that offer enhanced automation and high-throughput capabilities is growing rapidly across pharmaceutical, biotechnology, and academic sectors, as these advancements are essential for accelerating research, drug development, and the overall progress of genomic medicine

Oligonucleotide Synthesis Market Dynamics

Driver

“Growing Demand for Personalized Medicine and Advanced Therapies”

  • The increasing adoption of personalized medicine, which tailor treatments to individual genetic profiles, is a significant driver for the heightened demand for oligonucleotide synthesis. This is coupled with the rapid development and approval of advanced oligonucleotide-based therapies for a wide range of diseases

    • For instance, the consistent growth in regulatory approvals for oligonucleotide-based drugs, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), for conditions such as neurological disorders and rare genetic diseases, showcases their therapeutic potential. Companies such as Ionis Pharmaceuticals and Alnylam Pharmaceuticals are at the forefront of developing such therapies

  • As the understanding of genetic mechanisms underlying diseases deepens, oligonucleotides offer highly specific and effective therapeutic interventions, providing a compelling alternative to traditional drug modalities. Their ability to target specific genes and pathways makes them ideal for personalized approaches
  • Furthermore, the escalating investments in genomics and proteomics research, combined with advancements in gene editing technologies such as CRISPR-Cas9, are expanding the applications of synthesized oligonucleotides. These technologies rely heavily on custom-designed oligonucleotides for precise genetic manipulation and analysis
  • The strong clinical pipeline for oligonucleotide drugs and the continuous focus on developing targeted therapies are key factors propelling the adoption of oligonucleotide synthesis in both pharmaceutical and biotechnology sectors. The increasing collaboration between academic institutions and industry players further contributes to market growth

Restraint/Challenge

“High Cost of Synthesis and Purification, and Scalability Issues”

  • The high cost associated with synthesizing and purifying oligonucleotides, particularly for longer and more complex sequences, poses a significant challenge to the widespread adoption and commercialization of oligonucleotide-based therapeutics. This is compounded by inherent scalability issues in current synthesis technologies

    • For instance, the raw materials, especially phosphoramidites, are expensive, and the multi-step chemical synthesis process, while precise, can lead to the formation of impurities Rigorous and often complex purification methods such as HPLC are then required to achieve the high purity levels necessary for therapeutic applications, further driving up costs

  • ·Addressing these cost and purity challenges through improved synthesis efficiency, novel chemistries, and more cost-effective purification technologies is crucial for expanding market access. Companies are exploring enzymatic synthesis and other innovative methods to reduce reliance on expensive chemical reagents and processes
  • Furthermore, scaling up oligonucleotide production from research quantities to commercial demands presents significant technical hurdles. Traditional solid-phase synthesis methods, while effective for small scales, often struggle to maintain efficiency and quality at larger volumes, leading to challenges in meeting the growing demand for therapeutic-grade oligonucleotides
  • Overcoming these challenges through the development of more scalable, cost-efficient, and high-purity synthesis platforms will be vital for sustained market growth and the broader clinical application of oligonucleotide therapeutics

Oligonucleotide Synthesis Market Scope

The market is segmented on the basis of product, type, application, and end-user.

  • By Product

On the basis of product, the oligonucleotide synthesis market is segmented into oligonucleotides, reagents, and equipment. The oligonucleotides segment held the largest market share in 204. This dominance is driven by their fundamental role as the core product used across therapeutic applications, diagnostics, and extensive research. As the direct output of the synthesis process, the sheer volume and value of synthesized oligonucleotides establish their leading position.

The reagents segment is projected to exhibit the fastest growth from 2025 to 2032. This rapid expansion is fueled by the continuous and increasing demand for specialized chemicals and consumables required for oligonucleotide synthesis, directly correlating with the rising throughput and expanding scale of production, as well as advancements in synthesis chemistries. The equipment segment, while smaller, supports the industry through innovations in automated synthesizers crucial for high-throughput production

  • By Type

On the basis of type, the oligonucleotide synthesis market is segmented into custom oligos and predesigned oligos. The custom oligos segment held the largest market share in 2024, due to the surging demand for personalized medicine and highly targeted therapies, which necessitate unique, tailor-made oligonucleotide sequences for specific genetic targets and individual patient needs. Furthermore, extensive research and development activities, especially in cutting-edge fields such as gene editing and molecular biology, heavily rely on the precision and flexibility offered by custom-designed sequences.

The predesigned oligos segment is projected to witness the fastest growth, driven by their increasing adoption in routine research and diagnostic applications that require standardized, ready-to-use sequences, offering convenience, cost-effectiveness, and efficiency in high-throughput settings.

  • By Application

On the basis of application, the oligonucleotide synthesis market is segmented into therapeutic applications, diagnostics, research, and others. The therapeutic applications segment is projected to dominate the market with a market share of 42.7% in 2024, fueled by the accelerating pace of drug discovery and development focused on oligonucleotide-based therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs, for treating a wide range of diseases, particularly challenging conditions such as neurological disorders, rare genetic diseases, and even cardiovascular conditions. The increasing number of regulatory approvals for these novel drugs and a robust clinical pipeline further underpin this segment's substantial growth

The diagnostics segment is expected to witness the fastest growth, driven by the expanding use of oligonucleotide probes and primers in molecular diagnostics for infectious diseases, genetic testing, and companion diagnostics, benefiting from increased demand for accurate and rapid detection methods.

  • By End User

On the basis of end user, the oligonucleotide synthesis market is segmented into academic research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Pharmaceutical and biotechnology companies held the largest market revenue share in 2024. This dominance stems from their substantial R&D investments aimed at developing novel oligonucleotide-based drugs, conducting high-throughput screening for drug candidates, and the increasing demand for high-quality, large-scale oligonucleotide synthesis required for preclinical and clinical trials

The diagnostic laboratories segment is expected to emerge as the fastest-growing end-user segment. This rapid expansion is driven by the increasing adoption of molecular diagnostics for various diseases, the rising demand for genetic testing, and the continuous development of new diagnostic assays that heavily rely on synthesized oligonucleotides. Academic research institutes also hold a significant market share, serving as crucial centers for fundamental research in genomics, molecular biology, and gene expression studies

Oligonucleotide Synthesis Market Regional Analysis

  • North America dominates the oligonucleotide synthesis market with the largest revenue share of 40.7% in 2024, driven by its well-established biotechnology and pharmaceutical industries, substantial R&D spending, and early adoption of cutting-edge biotechnologies. The region benefits from a strong presence of key industry players and significant investments in genomics and precision medicine initiatives
  • The region benefits from substantial funding for life science research, a strong presence of key market players, and a growing focus on personalized medicine and gene therapy, which are heavily reliant on synthesized oligonucleotides
  • This widespread adoption is further supported by a robust healthcare infrastructure, increasing collaborations between academic institutions and industry, and a favorable regulatory environment, positioning North America as a leader in oligonucleotide production and application

U.S. Oligonucleotide Synthesis Market Insight

The U.S. oligonucleotide synthesis market captured the largest revenue share within North America, fueled by its unparalleled leadership in biotechnology and pharmaceutical R&D. The nation's robust ecosystem of biotech companies, academic institutions, and significant government and private funding for life sciences propels the demand for synthesized oligonucleotides. Growing investments in gene therapy, personalized medicine, and advanced molecular diagnostics, coupled with a high adoption rate of cutting-edge technologies such as CRISPR, further contribute to the market's expansion.

Europe Oligonucleotide Synthesis Market Insight

The Europe oligonucleotide synthesis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by its strong base of pharmaceutical and biotechnology companies and escalating investments in genomics research. The region's well-established academic research infrastructure, coupled with increasing prevalence of chronic and genetic diseases, fosters the demand for oligonucleotide-based therapeutics and diagnostics. Supportive government initiatives and a collaborative research environment across European countries further stimulate market growth.

U.K. Oligonucleotide Synthesis Market Insight

The U.K. oligonucleotide synthesis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by its world-class research universities, a flourishing biotech sector, and significant government funding in genomics and precision medicine initiatives. The country's strong focus on advanced healthcare solutions and drug discovery, particularly in areas such as RNA therapeutics and gene editing, encourages the adoption of high-quality synthesized oligonucleotides. The U.K.'s robust regulatory framework and research infrastructure are expected to continue to stimulate market growth.

Germany Oligonucleotide Synthesis Market Insight

The Germany oligonucleotide synthesis market is expected to expand at a considerable CAGR during the forecast period, fueled by its strong pharmaceutical industry, high R&D spending, and a pronounced focus on precision medicine and advanced molecular diagnostics. Germany’s well-developed scientific infrastructure, combined with its emphasis on innovation in healthcare, promotes the adoption of oligonucleotide synthesis in both academic and industrial settings. The integration of genomic research into clinical practice is also becoming increasingly prevalent, aligning with local consumer expectations for advanced medical solutions.

Asia-Pacific Oligonucleotide Synthesis Market Insight

The Asia-Pacific oligonucleotide synthesis market is poised to grow at the fastest CAGR of 14.8% during the forecast period, driven by increasing R&D investments, rising disposable incomes, and technological advancements in countries such as China, Japan, and India. The region's growing inclination towards advanced healthcare, supported by government initiatives promoting biotechnology and pharmaceutical development, is driving the adoption of oligonucleotide synthesis. Furthermore, as APAC emerges as a prominent hub for contract research and manufacturing organizations the accessibility and affordability of oligonucleotide synthesis services are expanding to a wider research and industrial base.

Japan Oligonucleotide Synthesis Market Insight

The Japan oligonucleotide synthesis market is gaining momentum due to the country’s high-tech research culture, significant investments in life sciences, and demand for advanced medical solutions. The Japanese market places a significant emphasis on genetic research and drug discovery, and the adoption of oligonucleotide synthesis is driven by the increasing number of biotechnology ventures and pharmaceutical R&D activities. The integration of oligonucleotides in various applications, such as genetic testing and gene therapy, is fueling growth. Moreover, Japan's aging population is likely to spur demand for novel diagnostic and therapeutic solutions in both academic and clinical sector.

India Oligonucleotide Synthesis Market Insight

The India oligonucleotide synthesis market accounted for a significant market revenue share in Asia Pacific in 2024, attributed to the country's expanding biotechnology sector, increasing R&D activities, and a large pool of skilled scientific professionals. India stands as a growing hub for contract research and manufacturing, and oligonucleotide synthesis is becoming increasingly popular in academic research, pharmaceutical development, and diagnostic applications. The push towards affordable healthcare solutions and the availability of cost-effective research services, alongside strong domestic scientific capabilities, are key factors propelling the market in India.

Oligonucleotide Synthesis Market Share

The oligonucleotide Synthesis industry is primarily led by well-established companies, including:

  • Integrated DNA Technologies, Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Twist Bioscience (U.S.)
  • Merck KGaA (Germany)
  • Agilent Technologies, Inc. (U.S.)
  • Eurofins Scientific (Luxembourg)
  • LGC Limited (U.K.)
  • GenScript (U.S.)
  • Danaher Corporation (U.S.)
  • Sarepta Therapeutics, Inc. (U.S.)
  • Ionis Pharmaceuticals, Inc. (U.S.)
  • Alnylam Pharmaceuticals, Inc. (U.S.)
  • Nitto Avecia (U.S.)
  • TriLink BioTechnologies (U.S.)
  • Bio-Synthesis Inc. (U.S.)
  • Ajinomoto Bio-Pharma (Japan)
  • ATDBio Ltd (U.K.)
  • Microsynth AG (Switzerland)
  • Macrogen Inc. (South Korea)
  • Kaneka Eurogentec S.A. (Belgium)

Latest Developments in Global Oligonucleotide Synthesis Market

  • In December 2024, Co-Diagnostics, Inc. and its Indian joint venture, CoSara Diagnostics Pvt. Ltd., inaugurated CoSara's oligonucleotide synthesis facility in Ranoli, India. This new facility is designed to support the "Make in India" initiative by manufacturing the company's patented Co-Primers chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests
  • In November 2023, Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA, launched Twist Express Genes. This new gene synthesis service boasts a rapid order-to-shipping turnaround time of five to seven business days, significantly accelerating research and development workflows in gene editing, drug discovery, and other genomic applications
  • In October 2023, Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation, announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa. This significant milestone marks IDT's entrance into the therapeutics space, enabling the manufacture of cGMP-grade cell and gene therapy reagents to support the growing demand in genomic medicine
  • In May 2023, Twist Bioscience Corporation and CeGaT GmbH announced a collaboration to launch the Twist Alliance CeGaT RNA Fusion Panel. This joint effort aims to provide a specialized tool for oncology research, facilitating the efficient detection of RNA fusions and enabling transcript variant analysis in cancer studies, showcasing increasing collaboration in targeted research solutions
  • In February 2023, Fluor Corporation announced it was selected by Agilent Technologies, Inc. to provide engineering and procurement services for the expansion of Agilent's oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. This collaboration signifies a major investment in expanding large-scale production capabilities for therapeutic oligonucleotides, critical for meeting the growing demand in genetic medicine


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

Companies such as Integrated DNA Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Twist Bioscience (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), are major players in oligonucleotide synthesis market.

In December 2024, Co-Diagnostics, Inc. and its Indian joint venture, CoSara Diagnostics Pvt. Ltd., inaugurated CoSara's oligonucleotide synthesis facility in Ranoli, India. This new facility is designed to support the "Make in India" initiative by manufacturing the company's patented Co-Primers chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests. In November 2023, Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA, launched Twist Express Genes. This new gene synthesis service boasts a rapid order-to-shipping turnaround time of five to seven business days, significantly accelerating research and development workflows in gene editing, drug discovery, and other genomic applications

The countries covered in the oligonucleotide Synthesis market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.

Testimonial
Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future